Publications by authors named "K Kvacheniuk"

4 Publications

  • Page 1 of 1

[INFLUENCE OF COMBINED ERADICATION AND PROKINETIC THERAPY ON CLINICAL MANIFESTATIONS, PSYCHOLOGICAL STATUS AND QUALITY OF LIFE OF PATIENTS WITH FUNCTIONAL DYSPEPSIA - POSTPRANDIAL DISTRESS SYNDROME: RANDOMIZED PROSPECTIVE STUDY].

Georgian Med News 2021 Mar(312):61-67

1Bogomolets National Medical University, Kyiv; Ukraine.

Functional dyspepsia - postprandial distress-syndrome (FD-PDS) is one of the most common reasons for seeking medical attention of general practitioners, internists and gastroenterologists worldwide. Standard approaches to the treatment of patients with postprandial distress syndrome are only effective in small amount of cases. Aim of the study - comparative assessment of the effectiveness of combined eradication and prokinetic therapy and eradication therapy only in the treatment of FD-PDS by studying their effect on the clinical manifestations of the disease, patients' psychological status and quality of life. This was a randomized prospective study among patients with FD-PDS in the presence of Helicobater pylori invasion. Participants from group 1 - 65 patients - received eradication therapy and prokinetic itoprid hydrochloride 50 mg three times a day; participants in group 2 - 61 patients - received only eradication therapy for 14 days. Helicobacter pylori was evaluated using a rapid one-step immunochromatographic test to detect stool antigen, or using PCR for Helicobacter pylori DNA, or using a histological method. To assess the severity of dyspeptic and concomitant gastroenterological symptoms, a 7-point Likert scale was used; to assess the severity of anxiety and depression in dynamics - Hospital Anxiety and Depression Scale (HADS); to assess the quality of life indicators - the SF-36 questionnaire. The duration of the study was 30 days. Combined eradication and prokinetic therapy, in comparison with eradication therapy only, is more effective in the treatment of FD-PDS. The additional use of itopride hydrochloride contributes to a more effective decrease in the severity and a longer elimination of symptoms of the disease (p˂0.05), helps to reduce the level of depression (p=0.002) and improve the quality of life indicators on the scales of physical functioning (p=0.032), role-physical functioning (p=0.039), bodily pain (p=0.0001), general health (p = 0.041), vitality (p=0.0001), social functioning (p=0.048).
View Article and Find Full Text PDF

Download full-text PDF

Source
March 2021

[CAPSUMEN IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME].

Georgian Med News 2019 Apr(289):94-102

1Bogomolets National Medical University, Kyiv; 3Мedical Centre "Universal Clinic "Oberig", Kyiv.

Irritable bowel syndrome (IBS) is a common functional intestinal disorder, the frequency of which varies from 5% to 20% in the population depending on the geographical region and the criteria used for diagnosis. Aim of the study - to compare the clinical course of the IBS symptoms in patients receiving and not receiving capsumen. A cross-sectional study was conducted and it included adult patients with IBS. The study included 112 patients with IBS with diarrhea and constipation, which amounted to 4 groups: 1st group - 35 patients with IBS with diarrhea, who was managed in treatment with capsumen, 2nd group - 21 patients with IBS with diarrhea, who does not received capsumen, 3rd group - 34 patients with IBS with constipation, who received capsumen, 4th group - 22 patients with IBS with constipation, who does not received capsumen. Capsumen statistically significantly contributed to the reduction (disappearance) of abdominal pain in IBS patients with diarrhea and constipation already on the 2nd week of treatment. When capsumen was used the fastest positive dynamics in the reduction (disappearance) of meteorism was observed. Capsumen helps to relieve diarrhea and constipation on the 2nd week of treatment. Capsumen contributes to the normalization of intestinal microflora (growth of the obligate flora, reduction of conditionally-pathogenic, normalization of the indicator F/B). Capsumen application helps to improve the quality of life of patients with IBS, reducing the frequency of anxiety and depression.
View Article and Find Full Text PDF

Download full-text PDF

Source
April 2019

[The current possibilities for treating chronic viral hepatitides].

Lik Sprava 1999 Sep(6):45-8

The article addresses on the modern level the issues of treatment of chronic viral hepatitis (ChVH). Recent data are submitted on those drugs and their combinations being employed in the treatment of ChVH. Considered in the paper in some detail is alpha-interferon, indications and contraindications, with schedules of treatment submitted for most frequently encountering chronic hepatitis B, C, D, as well as little-studied hepatitis G. Side effects of interferon therapy are described.
View Article and Find Full Text PDF

Download full-text PDF

Source
September 1999

[The use of Flamikar in patients with chronic hepatitis of alcoholic etiology].

Authors:
K L Kvacheniuk

Lik Sprava 1999 Apr-May(3):142-4

Clinical efficacy was studied of flamicar in patients with chronic hepatitis of alcohol etiology. Flamicar by 21-day courses was found to lower the degree of clinical symptoms of the illness, making for improvement of somatic condition of the patient, returning the indices for the functional state of the liver to normal. Thus, flamicar is an effective remedy for patients with chronic alcohol hepatitis.
View Article and Find Full Text PDF

Download full-text PDF

Source
October 1999